Clinical trials: Early Release of Chromogranin A (CgA)
Early Release of Chromogranin A (CgA)
Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT
The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.
- Trial name
- NCT06183047
- Testing
- early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
- Volunteers
- 38 people
- Sponsor
- Military Institute od Medicine National Research Institute